5459 related articles for article (PubMed ID: 21545758)
1. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
[TBL] [Abstract][Full Text] [Related]
2. How do patients contribute to signal detection? : A retrospective analysis of spontaneous reporting of adverse drug reactions in the UK's Yellow Card Scheme.
Hazell L; Cornelius V; Hannaford P; Shakir S; Avery AJ;
Drug Saf; 2013 Mar; 36(3):199-206. PubMed ID: 23444232
[TBL] [Abstract][Full Text] [Related]
3. Adverse drug reaction reporting in the UK: a retrospective observational comparison of yellow card reports submitted by patients and healthcare professionals.
McLernon DJ; Bond CM; Hannaford PC; Watson MC; Lee AJ; Hazell L; Avery A;
Drug Saf; 2010 Sep; 33(9):775-88. PubMed ID: 20701410
[TBL] [Abstract][Full Text] [Related]
4. How patient reporters identify adverse drug reactions: a qualitative study of reporting via the UK Yellow Card Scheme.
Krska J; Anderson C; Murphy E; Avery AJ
Drug Saf; 2011 May; 34(5):429-36. PubMed ID: 21513365
[TBL] [Abstract][Full Text] [Related]
5. Patient views and experiences of making adverse drug reaction reports to the Yellow Card Scheme in the UK.
McLernon DJ; Bond CM; Lee AJ; Watson MC; Hannaford PC; Fortnum H; Krska J; Anderson C; Murphy E; Avery A;
Pharmacoepidemiol Drug Saf; 2011 May; 20(5):523-31. PubMed ID: 21328634
[TBL] [Abstract][Full Text] [Related]
6. Pharmacovigilance Reports Received from Children and Young People, and Development of Information to Aid Future Reporting from this Age Group.
Bhoombla N; Preston J; Ainsworth J; Bird H; Jadeja M; King C; Hawcutt DB
Paediatr Drugs; 2020 Jun; 22(3):335-341. PubMed ID: 32253722
[TBL] [Abstract][Full Text] [Related]
7. Nonmedical prescriber experiences of training and competence to report adverse drug reactions in the UK.
Thompson A; Randall C; Howard J; Barker C; Bowden D; Mooney P; Munyika A; Smith S; Pirmohamed M
J Clin Pharm Ther; 2019 Feb; 44(1):78-83. PubMed ID: 30206951
[TBL] [Abstract][Full Text] [Related]
8. Identifying and managing adverse drug reactions: Qualitative analysis of patient reports to the UK yellow card scheme.
O' Donovan B; Rodgers RM; Cox AR; Krska J
Br J Clin Pharmacol; 2022 Jul; 88(7):3434-3446. PubMed ID: 35128732
[TBL] [Abstract][Full Text] [Related]
9. Public awareness in Wales of the UK Yellow Card scheme for reporting suspected adverse drug reactions.
Bracchi RC; Tseliou F; Copeland L; Routledge PA; Thomas A; Woods F; Adams A; Walker J; Jadeja M; Atkinson MD; Ashfield-Watt P
Br J Clin Pharmacol; 2021 Aug; 87(8):3344-3348. PubMed ID: 33386761
[TBL] [Abstract][Full Text] [Related]
10. First French experience of ADR reporting by patients after a mass immunization campaign with Influenza A (H1N1) pandemic vaccines: a comparison of reports submitted by patients and healthcare professionals.
Durrieu G; Palmaro A; Pourcel L; Caillet C; Faucher A; Jacquet A; Ouaret S; Perault-Pochat MC; Kreft-Jais C; Castot A; Lapeyre-Mestre M; Montastruc JL;
Drug Saf; 2012 Oct; 35(10):845-54. PubMed ID: 22967189
[TBL] [Abstract][Full Text] [Related]
11. Survey to assess public awareness of patient reporting of adverse drug reactions in Great Britain.
Fortnum H; Lee AJ; Rupnik B; Avery A;
J Clin Pharm Ther; 2012 Apr; 37(2):161-5. PubMed ID: 21592158
[TBL] [Abstract][Full Text] [Related]
12. The importance of direct patient reporting of suspected adverse drug reactions: a patient perspective.
Anderson C; Krska J; Murphy E; Avery A;
Br J Clin Pharmacol; 2011 Nov; 72(5):806-22. PubMed ID: 21496066
[TBL] [Abstract][Full Text] [Related]
13. An observational study to compare the contents and quality of information furnished in CDSCO ADR reporting form, yellow card, medwatch and blue form by the healthcare professionals.
Rehan HS; Chopra D; Holani SN; Mishra R
Int J Risk Saf Med; 2014; 26(1):1-8. PubMed ID: 24796346
[TBL] [Abstract][Full Text] [Related]
14. Spontaneous adverse drug reaction reporting by patients in Canada: a multi-method study-study protocol.
Dweik RA; Yaya S; Stacey D; Kohen D
Springerplus; 2016; 5():213. PubMed ID: 27026907
[TBL] [Abstract][Full Text] [Related]
15. Language does not come "in boxes": Assessing discrepancies between adverse drug reactions spontaneous reporting and MedDRA® codes in European Portuguese.
Inácio P; Airaksinen M; Cavaco A
Res Social Adm Pharm; 2015; 11(5):664-74. PubMed ID: 25596069
[TBL] [Abstract][Full Text] [Related]
16. Assessing and further developing age-appropriate information for young people about reporting suspected adverse drug reactions.
Bioletti L; ; Woodward C; Jadeja M; Hawcutt DB
Br J Clin Pharmacol; 2024 Mar; 90(3):863-870. PubMed ID: 37990602
[TBL] [Abstract][Full Text] [Related]
17. Are consumers ready to take part in the Pharmacovigilance System?--a Portuguese preliminary study concerning ADR reporting.
Matos C; van Hunsel F; Joaquim J
Eur J Clin Pharmacol; 2015 Jul; 71(7):883-90. PubMed ID: 26004569
[TBL] [Abstract][Full Text] [Related]
18. The value of patient reporting to the pharmacovigilance system: a systematic review.
Inácio P; Cavaco A; Airaksinen M
Br J Clin Pharmacol; 2017 Feb; 83(2):227-246. PubMed ID: 27558545
[TBL] [Abstract][Full Text] [Related]
19. Patient versus healthcare professional spontaneous adverse drug reaction reporting: a systematic review.
Inch J; Watson MC; Anakwe-Umeh S
Drug Saf; 2012 Oct; 35(10):807-18. PubMed ID: 22928729
[TBL] [Abstract][Full Text] [Related]
20. Online reporting of adverse drug reactions: a study from a French regional pharmacovigilance center.
Abadie D; Chebane L; Bert M; Durrieu G; Montastruc JL
Therapie; 2014; 69(5):395-400. PubMed ID: 25269141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
